Cellectis, a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART), has closed the sale of its subsidiary Cellectis AB to Takara Bio Inc., an innovative biotechnology company based in Shiga, Japan. The financials terms have not been disclosed.
The company now concentrates its activities in the field of oncology through the development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy products generated through its allogeneic CAR-T platform, both on its own as well as in partnership with Servier and Pfizer.
Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer.
As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin reagent, which is a world-standard in gene therapy protocols.